Llauradó Marta, Majem Blanca, Altadill Tatiana, Lanau Lucia, Castellví Josep, Sánchez-Iglesias Jose Luis, Cabrera Silvia, De la Torre Javier, Díaz-Feijoo Berta, Pérez-Benavente Asuncion, Colás Eva, Olivan Mireia, Doll Andreas, Alameda Francesc, Matias-Guiu Xavier, Moreno-Bueno Gema, Carey Mark S, Del Campo Josep Maria, Gil-Moreno Antonio, Reventós Jaume, Rigau Marina
Faculty of Medicine, University of British Columbia, Vancouver, Canada; Research Unit in Biomedicine and Translational Oncology, Vall Hebron Research Institute University Hospital, Barcelona, Spain.
Research Unit in Biomedicine and Translational Oncology, Vall Hebron Research Institute University Hospital, Barcelona, Spain.
Mol Cell Endocrinol. 2014 Jun 5;390(1-2):73-84. doi: 10.1016/j.mce.2014.03.006. Epub 2014 Apr 18.
Ovarian cancer (OC) is the most lethal gynecological malignancy among women. Over 70% of women with OC are diagnosed in advanced stages and most of these cases are incurable. Although most patients respond well to primary chemotherapy, tumors become resistant to treatment. Mechanisms of chemoresistance in cancer cells may be associated with mutational events and/or alterations of gene expression through epigenetic events. Although focusing on known genes has already yielded new information, previously unknown non-coding RNAs, such as microRNAs (miRNAs), also lead insight into the biology of chemoresistance. In this review we summarize the current evidence examining the role of miRNAs as biomarkers of response and survival to therapy in OC. Beside their clinical implications, we also discuss important differences between studies that may have limited their use as clinical biomarkers and suggest new approaches.
卵巢癌（OC）是女性中最致命的妇科恶性肿瘤。超过70%的卵巢癌女性患者在晚期被诊断出来，其中大多数病例无法治愈。尽管大多数患者对初始化疗反应良好，但肿瘤会产生耐药性。癌细胞中的化疗耐药机制可能与突变事件和/或通过表观遗传事件导致的基因表达改变有关。尽管聚焦于已知基因已经产生了新的信息，但以前未知的非编码RNA，如微小RNA（miRNA），也为化疗耐药生物学提供了见解。在这篇综述中，我们总结了目前有关miRNA作为卵巢癌治疗反应和生存生物标志物作用的证据。除了它们的临床意义外，我们还讨论了可能限制其作为临床生物标志物使用的研究之间的重要差异，并提出了新的方法。
